0000950170-22-000333.txt : 20220114 0000950170-22-000333.hdr.sgml : 20220114 20220114173020 ACCESSION NUMBER: 0000950170-22-000333 CONFORMED SUBMISSION TYPE: 8-K/A PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20210810 ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220114 DATE AS OF CHANGE: 20220114 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Recro Pharma, Inc. CENTRAL INDEX KEY: 0001588972 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 261523233 STATE OF INCORPORATION: PA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-36329 FILM NUMBER: 22532808 BUSINESS ADDRESS: STREET 1: 1 E. UWCHLAN AVE, SUITE 112 CITY: EXTON STATE: PA ZIP: 19341 BUSINESS PHONE: 770-534-8239 MAIL ADDRESS: STREET 1: 1 E. UWCHLAN AVE, SUITE 112 CITY: EXTON STATE: PA ZIP: 19341 8-K/A 1 reph-20210810.htm 8-K/A 8-K/A
0001588972true00015889722021-08-102021-08-10

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K/A

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 10, 2021

 

 

Recro Pharma, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

Pennsylvania

001-36329

26-1523233

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

1 E. Uwchlan Ave, Suite 112

 

Exton, Pennsylvania

 

19341

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: 770 534-8239

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common stock, par value $0.01

 

REPH

 

The NASDAQ Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

Explanatory Note

As previously reported in a Current Report on Form 8-K, filed with the Securities and Exchange Commission (the “SEC”) on August 13, 2021 (the “Original Report”), as amended and supplemented by a Current Report on Form 8-K/A, filed with the SEC on September 10, 2021 (the “Amended Report,” and collectively with the Original Report, the “Report”), Recro Pharma, Inc. (the “Company”) entered into a Unit Purchase Agreement (the “Purchase Agreement”) by and among the Company, IriSys, LLC, a California limited liability company (“IriSys”), IriSys, Inc., a California corporation (“IriSys Parent”), Continent Pharmaceuticals U.S., Inc., a Delaware corporation, and EPS Americas Corp., a Delaware corporation (collectively, the “Sellers”), and IriSys Parent, in its capacity as the representative of the Sellers, pursuant to which the Company agreed to purchase 100% of the outstanding units of IriSys from the Sellers (the “Acquisition”). The closing of the Acquisition occurred simultaneously with the execution of the Purchase Agreement. As a result of the Acquisition, IriSys became a wholly owned subsidiary of the Company.

This Current Report on Form 8-K/A (this “Amendment”) further amends and supplements the Report to include updated pro forma combined statements of operations for the nine months ended September 30, 2021.

The pro forma financial information included in this Amendment has been presented for informational purposes only and is not necessarily indicative of the combined results of operations that would have been realized had the Acquisition occurred as of the date indicated, nor is it meant to be indicative of any future results of operations that the Company will achieve after the Acquisition.
 

Item 9.01 Financial Statements and Exhibits.

(b) Pro Forma Financial Information.

The unaudited pro forma combined statement of operations for the nine months ended September 30, 2021 are filed as Exhibit 99.1 and incorporated by reference herein.

(d) Exhibits

Exhibit No.

 

Description

99.1

 

Unaudited pro forma combined statement of operations of Recro Pharma, Inc. for the nine months ended September 30, 2021

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

 

Recro Pharma, Inc.

 

 

 

 

Date:

January 14, 2022

By:

/s/ J. David Enloe, Jr.

 

 

Name:

J. David Enloe, Jr.

 

 

Title:

President and Chief Executive Officer

 

 EX-99.1 2 reph-ex99_1.htm EX-99.1 EX-99.1

 

Exhibit 99.1

Recro Pharma, Inc.

Unaudited Pro Forma Combined Statements of Operations

Nine Months Ended September 30, 2021

 

Recro

 

 

Pre-acquisition IriSys

 

 

 

 

 

 

 

 

Nine months ended September 30, 2021

 

 

Six months ended June 30, 2021

 

 

July 1 to August 12, 2021

 

 

Pro forma adjustments

 

 

Pro forma combined

 

(amounts in thousands, except share and per share data)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Revenue

$

53,057

 

 

$

6,844

 

 

$

1,142

 

 

$

—

 

 

$

61,043

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cost of sales

 

39,831

 

 

 

3,529

 

 

 

810

 

 

 

470

 

(a)

 

44,640

 

Selling, general and administrative

 

13,076

 

 

 

3,088

 

 

 

618

 

 

 

(1,211

)

(b)

 

15,571

 

Amortization of intangible assets

 

835

 

 

 

-

 

 

 

-

 

 

 

650

 

(c)

 

1,485

 

Total operating expenses

 

53,742

 

 

 

6,617

 

 

 

1,428

 

 

 

(91

)

 

 

61,696

 

Operating (loss) income

 

(685

)

 

 

227

 

 

 

(286

)

 

 

91

 

 

 

(653

)

Interest expense

 

(11,680

)

 

 

(87

)

 

 

(1

)

 

 

(402

)

(d)

 

(12,170

)

Gain on extinguishment of debt

 

3,352

 

 

 

866

 

 

 

-

 

 

 

-

 

 

 

4,218

 

Net (loss) income

$

(9,013

)

 

$

1,006

 

 

$

(287

)

 

$

(311

)

 

$

(8,605

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Loss per share:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic

$

(0.22

)

 

 

 

 

 

 

 

 

 

 

$

(0.18

)

Diluted

 

(0.22

)

 

 

 

 

 

 

 

 

 

 

 

(0.18

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted average shares outstanding

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic

 

40,137,069

 

 

 

 

 

 

 

 

 

7,667,075

 

(d)

 

47,804,144

 

Diluted

 

40,137,069

 

 

 

 

 

 

 

 

 

7,667,075

 

(d)

 

47,804,144

 

See notes to unaudited pro forma combined statements of operations.

 

1

 

Recro Pharma, Inc.

Notes to Unaudited Pro Forma Combined Statements of Operations

1. Description of the transaction

On August 13, 2021, Recro Pharma, Inc. (the “Company” or "Recro") entered into a Unit Purchase Agreement (the “Purchase Agreement”) by and among the Company, IriSys, LLC, a California limited liability company (“IriSys”), IriSys, Inc., a California corporation (“IriSys Parent”), Continent Pharmaceuticals U.S., Inc., a Delaware corporation, and EPS Americas Corp., a Delaware corporation (each, a “Seller” and collectively, the “Sellers”), and IriSys Parent, in its capacity as the representative of the Sellers, pursuant to which the Company agreed to purchase 100% of the outstanding units of IriSys from the Sellers (the “Acquisition”). The closing of the Acquisition (the “Closing”) occurred simultaneously with execution of the Purchase Agreement. As a result of the Acquisition, IriSys became a wholly owned subsidiary of the Company.

The total purchase price (the “Purchase Price”) payable by the Company for the Acquisition was approximately $49.85 million, subject to certain adjustments as provided in the Purchase Agreement based on transaction expenses, cash and cash equivalents, indebtedness and net working capital of IriSys at the Closing. The Purchase Price consisted of: (i) $25.5 million in cash paid to the Sellers at the Closing; (ii) 9,302,718 shares of the Company’s common stock, par value $0.01 per share, to be issued to the Sellers six (6) months after the Closing; and (iii) a subordinated promissory note issued to certain Sellers by the Company in the aggregate principal amount of approximately $6.1 million (the “Note”). The Note is unsecured, has a three-year term, and bears interest at a rate of six percent (6%) per annum. The Note may be prepaid in whole or in part at any time prior to the maturity date. The Note is expressly subordinated in right of payment and priority to the Company’s existing loans with Athyrium Capital Management issued under that certain Credit Agreement, dated as of November 17, 2017 (as amended from time to time, the “Credit Agreement”), by and among the Company, the Company’s subsidiaries named as guarantors therein (the “Guarantors”), the lenders party thereto (the “Lenders”), and Athyrium Opportunities III Acquisition LP (“Athyrium Opportunities III”) as administrative agent.

2. Basis of presentation

The accompanying unaudited pro forma combined statements of operations combine the historical consolidated statements of operations of Recro and those of IriSys after giving effect to the Acquisition, using the acquisition method of accounting in accordance with Accounting Standards Codification (“ASC”) 805, “Business Combinations”, and applying the assumptions and adjustments described in the accompanying notes. The accompanying unaudited pro forma combined statements of operations were prepared in accordance with Article 11 of Regulation S-X.

The unaudited pro forma combined statements of operations combine the operating results of Recro for the nine months ended September 30, 2021 (which includes the results of IriSys since August 13, 2021) with the operating results of IriSys both for the six months ended June 30, 2021 and for period from July 1, 2021 to August 12, 2021.

The unaudited pro forma combined statements of operations give effect to the Acquisition as if such acquisition had occurred on January 1, 2020. The historical consolidated financial statements have been adjusted in the pro forma combined financial statements to give effect to pro forma events that are (1) directly attributable to the business combination, (2) factually supportable and (3) expected to have a continuing impact on the combined results following the business combination. The unaudited pro forma combined statements of operations should be read in conjunction with the historical financial statements and the related notes thereto of Recro which are presented in Recro's Annual Report on Form 10-K for the year ended December 31, 2020, Recro's Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2021 as well as the historical financial statements of IriSys included as exhibits 99.1 and 99.2 to the Company’s Current Report on Form 8-K/A filed with the Securities and Exchange Commission (the “SEC”) on September 10, 2021. The unaudited pro forma combined statements of operations are presented for illustrative purposes only and are not necessarily indicative of the operating results that would have been achieved if the Acquisition had been consummated as of January 1, 2020, nor are they necessarily indicative of the future operating results of the combined company.

No effect has been given in these pro forma financial statements for additional ongoing costs or synergistic benefits that may be realized through the combination, nor has any effect been given to costs that may be incurred in integrating

2

 

operations. In addition, no adjustments have been made to eliminate non-recurring or unusual costs included in the historical results of Recro or IriSys, such as the gains on the extinguishment of debt included in the statement of operations.

Unaudited pro forma combined statements of operations for the year ended December 31, 2020 were included as exhibit 99.3 to the Company’s Current Report on Form 8-K/A filed with the SEC on September 10, 2021. Unaudited pro forma combined balance sheets are not provided herein because the balance sheet as of September 30, 2021 presented in Recro's Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2021 includes IriSys.

3. Estimated consideration and preliminary purchase price allocation

Recro accounted for the Acquisition as the purchase of a business under generally accepted accounting principles in the U.S. (U.S. GAAP). Under this method of accounting, the assets of IriSys will be recorded as of the acquisition date at their fair values and consolidated with Recro. The fair value estimates include, but are not limited to, future expected cash flows, revenue and expense projections, discount rates and revenue volatility. Recro is still in the process of assembling the information necessary to finalize the allocation of the total purchase price, which will likely change upon completion of this assessment process.

The aggregate purchase price consideration was comprised of cash consideration, a subordinated promissory note and a contractual obligation to issue 9,302,718 shares of the Company’s common stock on the six-month anniversary of the closing, subject to a working capital adjustment. The following table summarizes the estimated consideration paid:

 

August 13, 2021

 

Cash paid, net of cash acquired

$

24,006

 

Fair value of shares issuable to former equity holders of IriSys

 

20,931

 

Fair value of note with former equity holder of IriSys

 

5,240

 

Total estimated consideration

$

50,177

 

The fair value of the shares issuable was determined by using the price of the Company's common stock on the acquisition date, less a discount for lack of marketability due to the shares being unregistered shares of the Company. The fair value of the note was determined using a discounted cash flow analysis that incorporated an estimate of the market interest rate for debt of similar terms and credit risk on the acquisition date.

The Company incurred $1,211 in transaction costs related to the acquisition that were expensed as incurred and classified as selling, general and administrative expenses.

The following table summarizes the provisional fair values of the assets acquired and liabilities assumed at the date of acquisition:

3

 

 

As of August 13, 2021

 

Assets acquired:

 

 

Accounts receivable

$

912

 

Contract assets

 

505

 

Inventory

 

685

 

Prepaid expenses and other assets

 

91

 

Property and equipment

 

9,304

 

Right of use assets

 

5,559

 

Intangible assets

 

6,128

 

Goodwill

 

35,249

 

Other noncurrent liabilities

 

146

 

    Total assets acquired

$

58,579

 

 

 

 

Liabilities assumed:

 

 

Accounts payable

$

730

 

Accrued expenses and other liabilities

 

1,512

 

Operating lease liability

 

5,559

 

Debt from finance loan

 

415

 

Other liabilities

 

186

 

     Total liabilities assumed

$

8,402

 

 

 

 

Net assets acquired

$

50,177

 

The amounts above represent the Company's current provisional fair value estimates and are subject to subsequent adjustments as additional information is obtained and valuations are finalized during the measurement period. The primary areas of estimates that are not yet finalized include the final outcome of the net working capital adjustment, certain tangible assets acquired and liabilities assumed, as well as the identifiable intangible assets. The purchase price was allocated to the tangible assets and identifiable intangible assets acquired and liabilities assumed based on their acquisition date estimated fair values. The identifiable intangible assets consisting of customer relationships, acquired backlog and trademark and tradename were assigned provisional fair values of $4,830, $957 and $341, respectively. Customer relationships, acquired backlog, and trademarks and trade names are subject to amortization on a straight-line basis and are being amortized over 12, 2.4 and 1.5 years, respectively.

The fair value of property, plant and equipment was determined using a cost approach valuation method. The customer relationships and acquired backlog were valued using the multi-period excess earnings method and trademarks and trade names were valued using the relief from royalty method. These methods require several judgments and assumptions to determine the fair value of intangible assets, including revenue growth rates, discount rates, EBITDA margins, and tax rates, among others. These nonrecurring fair value measurements are Level 3 measurements within the fair value hierarchy.

Goodwill represents the excess of the purchase price over the net identifiable tangible and intangible assets acquired. The goodwill related to the acquisition was attributable to expected synergies, the value of the assembled workforce as well as the collective experience of the management team with regards to its operations, customers, and industry. The goodwill is deductible for tax purposes.

These preliminary estimates of fair value and estimated useful lives may be different from the amounts included in the final Acquisition accounting, and the difference could have a material impact on the accompanying unaudited pro forma combined financial statements.

4. Pro forma adjustments

Adjustments included in the pro forma adjustments column of the pro forma combined balance sheet and the pro forma combined statement of operations include the following:

(a)
Reflects adjustments to depreciation of $0.5 million based on the preliminary fair value estimates of IriSys property, plant and equipment, which are preliminary and subject to change.

4

 

(b)
Reflects the adjustment to selling, general and administrative expenses to exclude $1.2 million in transaction costs incurred related to the acquisition.
(c)
Reflects adjustments to amortization of $0.7 million based on the preliminary fair value estimates of identifiable intangible assets, which are preliminary and subject to change.
(d)
Reflects the repayment of historic indebtedness of IriSys at closing, which resulted in the elimination of $0.1 million of historic interest expense related to that indebtedness, as well as interest expense related to the issuance of a note to a former shareholder of IriSys of $0.5 million. Interest expense on the note was estimated using an effective rate of interest of approximately 15%.
(e)
Reflects the portion of the 9.3 million shares of common stock of Recro that are issuable to the former shareholders of IriSys six months after the date of the Acquisition that was not already included in the weighted average shares outstanding reported by Recro for the nine months ended September 30, 2021.

5

 EX-101.SCH 3 reph-20210810.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 100000 - Document - Document And Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 reph-20210810_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Cover [Abstract] Amendment Description Amendment Flag City Area Code Document Period End Date Document Type Entity Address, Address Line One Entity Address, City or Town Entity Address, Postal Zip Code Entity Address, State or Province Entity Central Index Key Entity Emerging Growth Company Entity File Number Entity Incorporation, State or Country Code Entity Registrant Name Entity Tax Identification Number Local Phone Number Pre-commencement Issuer Tender Offer Pre-commencement Tender Offer Title of 12(b) Security Security Exchange Name Soliciting Material Trading Symbol Written Communications EX-101.PRE 5 reph-20210810_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 6 R1.htm IDEA: XBRL DOCUMENT v3.21.4
Document And Entity Information
Aug. 10, 2021
Cover [Abstract]  
Document Type 8-K/A
Amendment Flag true
Document Period End Date Aug. 10, 2021
Entity Registrant Name Recro Pharma, Inc.
Entity Central Index Key 0001588972
Entity Emerging Growth Company false
Entity File Number 001-36329
Entity Incorporation, State or Country Code PA
Entity Tax Identification Number 26-1523233
Entity Address, Address Line One 1 E. Uwchlan Ave, Suite 112
Entity Address, City or Town Exton
Entity Address, State or Province PA
Entity Address, Postal Zip Code 19341
City Area Code 770
Local Phone Number 534-8239
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common stock, par value $0.01
Trading Symbol REPH
Security Exchange Name NASDAQ
Amendment Description As previously reported in a Current Report on Form 8-K, filed with the Securities and Exchange Commission (the “SEC”) on August 13, 2021 (the “Original Report”), as amended and supplemented by a Current Report on Form 8-K/A, filed with the SEC on September 10, 2021 (the “Amended Report,” and collectively with the Original Report, the “Report”), Recro Pharma, Inc. (the “Company”) entered into a Unit Purchase Agreement (the “Purchase Agreement”) by and among the Company, IriSys, LLC, a California limited liability company (“IriSys”), IriSys, Inc., a California corporation (“IriSys Parent”), Continent Pharmaceuticals U.S., Inc., a Delaware corporation, and EPS Americas Corp., a Delaware corporation (collectively, the “Sellers”), and IriSys Parent, in its capacity as the representative of the Sellers, pursuant to which the Company agreed to purchase 100% of the outstanding units of IriSys from the Sellers (the “Acquisition”). The closing of the Acquisition occurred simultaneously with the execution of the Purchase Agreement. As a result of the Acquisition, IriSys became a wholly owned subsidiary of the Company.This Current Report on Form 8-K/A (this “Amendment”) further amends and supplements the Report to include updated pro forma combined statements of operations for the nine months ended September 30, 2021. The pro forma financial information included in this Amendment has been presented for informational purposes only and is not necessarily indicative of the combined results of operations that would have been realized had the Acquisition occurred as of the date indicated, nor is it meant to be indicative of any future results of operations that the Company will achieve after the Acquisition.
XML 7 reph-20210810_htm.xml IDEA: XBRL DOCUMENT 0001588972 2021-08-10 2021-08-10 0001588972 true 8-K/A 2021-08-10 Recro Pharma, Inc. PA 001-36329 26-1523233 1 E. Uwchlan Ave, Suite 112 Exton PA 19341 770 534-8239 false false false false Common stock, par value $0.01 REPH NASDAQ false As previously reported in a Current Report on Form 8-K, filed with the Securities and Exchange Commission (the “SEC”) on August 13, 2021 (the “Original Report”), as amended and supplemented by a Current Report on Form 8-K/A, filed with the SEC on September 10, 2021 (the “Amended Report,” and collectively with the Original Report, the “Report”), Recro Pharma, Inc. (the “Company”) entered into a Unit Purchase Agreement (the “Purchase Agreement”) by and among the Company, IriSys, LLC, a California limited liability company (“IriSys”), IriSys, Inc., a California corporation (“IriSys Parent”), Continent Pharmaceuticals U.S., Inc., a Delaware corporation, and EPS Americas Corp., a Delaware corporation (collectively, the “Sellers”), and IriSys Parent, in its capacity as the representative of the Sellers, pursuant to which the Company agreed to purchase 100% of the outstanding units of IriSys from the Sellers (the “Acquisition”). The closing of the Acquisition occurred simultaneously with the execution of the Purchase Agreement. As a result of the Acquisition, IriSys became a wholly owned subsidiary of the Company.This Current Report on Form 8-K/A (this “Amendment”) further amends and supplements the Report to include updated pro forma combined statements of operations for the nine months ended September 30, 2021. The pro forma financial information included in this Amendment has been presented for informational purposes only and is not necessarily indicative of the combined results of operations that would have been realized had the Acquisition occurred as of the date indicated, nor is it meant to be indicative of any future results of operations that the Company will achieve after the Acquisition. EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.4 html 1 118 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document And Entity Information Sheet http://www.recropharma.com/20210810/taxonomy/role/DocumentDocumentAndEntityInformation Document And Entity Information Cover 1 false false All Reports Book All Reports reph-20210810.htm reph-20210810.xsd reph-20210810_lab.xml reph-20210810_pre.xml reph-ex99_1.htm http://xbrl.sec.gov/dei/2021 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "reph-20210810.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "reph-20210810.htm" ] }, "labelLink": { "local": [ "reph-20210810_lab.xml" ] }, "presentationLink": { "local": [ "reph-20210810_pre.xml" ] }, "schema": { "local": [ "reph-20210810.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 118, "memberCustom": 0, "memberStandard": 0, "nsprefix": "reph", "nsuri": "http://www.recropharma.com/20210810", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "reph-20210810.htm", "contextRef": "C_5419959c-9fd0-45b5-82a2-329e32ce6587", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document And Entity Information", "role": "http://www.recropharma.com/20210810/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "reph-20210810.htm", "contextRef": "C_5419959c-9fd0-45b5-82a2-329e32ce6587", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.recropharma.com/20210810/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.recropharma.com/20210810/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.recropharma.com/20210810/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.recropharma.com/20210810/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.recropharma.com/20210810/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.recropharma.com/20210810/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.recropharma.com/20210810/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.recropharma.com/20210810/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.recropharma.com/20210810/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.recropharma.com/20210810/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.recropharma.com/20210810/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.recropharma.com/20210810/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.recropharma.com/20210810/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.recropharma.com/20210810/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.recropharma.com/20210810/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.recropharma.com/20210810/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.recropharma.com/20210810/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.recropharma.com/20210810/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.recropharma.com/20210810/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.recropharma.com/20210810/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.recropharma.com/20210810/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.recropharma.com/20210810/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.recropharma.com/20210810/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 14 0000950170-22-000333-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-22-000333-xbrl.zip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end